A Study of Ruxolitinib in Pancreatic Cancer Patients (Q67134539)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Study of Ruxolitinib in Pancreatic Cancer Patients |
clinical trial |
Statements
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study) (English)
0 references
June 2014
0 references
February 2016
0 references
86
0 references
18 year
0 references